FPRL1/FPR2 Antibody

Product Discontinued

FPRL1/FPR2 Antibody Summary

• Immunogen: Peptide with sequence EEVSYESAGYTVLR-C corresponding to N-Terminus according to NP_001453.1.
• Epitope: EEVSYESAGYTVLR-C
• Specificity: Reported variants represent identical protein: NP_001005738.1 and NP_001453.1.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FPR2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Peptide ELISA Detection limit 1:64000
• Application Notes: WB: Preliminary experiments gave an approx. 49 kDa band in human peripheral blood mononucleocytes, and cell line U93l7 lysates after 1 ug/ml antibody staining. Please note that currently we cannot find an explanation in the literature for the band we observe given the calculated size of 39.0 kDa band according to NP_001453.1. The 49 kDa band was successfully blocked by incubation with the immunizing peptide.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris (pH 7.3), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Notes

Please note, this antibody is considered Innovators Grade. Innovators Grade antibodies are generally unvalidated and require additional characterization for most new species/applications. Novus has made these antibodies available through our Innovators Reward program. Complete an online review with image, detailing your positive or negative results. In return, you receive a discount voucher for 100% of the purchase price of the reviewed product. Please contact us at innovators@novusbio.com for more details.

Alternate Names for FPRL1/FPR2 Antibody

• ALXR
• FMLP-R-I
• FMLP-R-II
• FMLPX
• formyl peptide receptor 2
• Formyl peptide receptor-like 1RFP
• FPR2
• FPR2A
• FPRH1FMLP-related receptor I
• FPRL1
• FPRL1LXA4 receptor
• HM63
• HM63FPRH2
• lipoxin A4 receptor (formyl peptide receptor related)
• Lipoxin A4 receptor
• LXA4 Receptor
• LXA4RFMLP-R-I
• N-formyl peptide receptor 2
• RFP

Background

The chemokine FPRL1 plays a role in the production of chemokine CCL2 by serum amyloid A. FPRL1 is a potent mediator in the activation of CRAC channels. Our results indicate that severe asthma is characterized by decreased airway LXA4 levels and luekocyte AKX receptor availability. Proinflammatory effect of VIP is mediated via the specific G protein-coupled receptor VIP/pituitary adenylate cyclase-activating protein (VPAC1) receptor as well as via FPRL1. Both intra- and extracellular Ca2+ play a role in controlling pro-inflammatory functions stimulated by PACAP which acts through a VPAC-1, FPRL1/Galphai/PI3K/ERK pathway and a VPAC-1/Galphas/PKA/p38 pathway to fully activate monocytes. To specifically inhibit the FPRL1 response the antagonist WRW(4) should be used. level of LXA4 in synovial fluid and lipoxin A4 receptor expression in synovial tissues obtained from patients with rheumatoid arthritis and osteoarthritis. FPRL-1 is capable of activating nuclear factor-kappa B (NF-kappaB) signaling through inhibitor-kappa B kinase (IKK) phosphorylation in human astrocytoma or Chinese hamster ovary cells. Piroxicam inhibits the neutrophil responses triggered through formyl peptide receptor, but not through formyl peptide receptor like 1 and this inhibition is due to a reduced binding of the activating ligand to its cell surface receptor. FPRL1 is a pituitary adenylate cyclase activating polypeptide (PACAP) 27-specific receptor. LXA(4) generated in or near the paracellular space via neutrophil-epithelial interactions can rapidly act on epithelial LXA(4)receptor to downregulate epithelial promotion of intestinal inflammation. cells transfected with FPRL1 gene exhibited markedly reduced tumorigenicity in syngeneic mice. association of the PDGFRbeta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2. results indicate that the cytokine-like property of serum amyloid A is manifested through activation of the Gi-coupled formyl peptide receptor-like 1(FPRL1/LXA4R). investigated the direct effect of LXA4 as well as the effect on agonist-induced biological responses using transfected HL-60 cells expressing FPR, FPRL1 or FPRL2. results showed that multiple domains in FPRL1 are involved in the receptor response to chemotactic agonists with the sixth transmembrane domain and the third extracellular loop playing a prominent role. Exocytosis of FPRL1 results in down-regulation of cytoplasmic FRPL1 in patients with pyoderma. Modulation of neutrophil FPRL1 by distinct peptide ligands activates a spectrum of cellular signaling events, including intracellular calcium concentration increase, phosphoinositide 3-kinase, extracellular signal-regulated kinase, and Akt activation. binding of SAA to FPRL1 may contribute to the destruction of bone and cartilage via the promotion of synoviocyte hyperplasia and angiogenesis. The N-formyl peptide receptors present in MSCs may play an important role in signaling stem cell adhesion, migration, and homing to injured and inflamed tissue for repair. The up-regulation of the A-SAA and FPRL1 genes in inflamed synovial tissue suggests an important role in the pathophysiology of inflammatory arthritis. an annexin 1 peptide can activate FPR, FPRL1, and FPRL2; results indicate that annexin 1 participates in regulating leukocyte emigration into inflamed tissue by activating and desensitizing different receptors of the FPR family.. FPR and FPRL1, use distinct signaling pathways in activation of human neutrophils. ligand-bound FPRL1 undergoes primarily clathrin-mediated and dynamin-dependent endocytosis. chemoattractant Trp-Lys-Tyr-Met-Val-D-Met activates eosinophils through the formyl peptide receptor and one of its homologues, formyl peptide receptor-like 1. serum amyloid A plays a role in the modulation of inflammatory and immune responses via FPRL1, by inducing matrix-metalloproteinase-9 upregulation. In view of the wide range of endogenous ligands known to interact with FPRL-1, including the anti-inflammatory protein annexin-A1, we speculate that the novel effect here described may impact on the clinical immunosuppressive. Analysis of in vitro expression of lipoxin A(4) receptor (ALX) on human neutrophils and the in vivo anti-inflammatory effect of glucocorticoids. Results show that humanin (HN) acts as a ligand for formyl peptide receptor-like 1 (FPRL1) and 2 (FPRL2).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FPRL1/FPR2 Antibody (NB100-94885)(1)

Publication using NB100-94885

• Mitchell D, O'Meara SJ, Gaffney A et al. The Lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J Biol Chem 2007-05-25 [PMID: 17403678]

FAQs for FPRL1/FPR2 Antibody (NB100-94885). (Showing 1 - 1 of 1 FAQ).

1. I am looking for an FPRL1 antibody that is reactive to mouse only. Does Novus have the antibody in question?
   • To answer your question, unfortunately all our FPRL1 antibodies are polyclonal and would detect both mouse and human formyl peptide receptor-like-1 and we do not have any mouse monoclonal antibody for it.

Bioinformatics

• Gene Symbol: FPR2
• Entrez:
  • 2358(Human)
• Uniprot:
  • NP_001005738.1(Human)